• Skip navigation
  • Skip to navigation
  • Skip to the bottom
Simulate organization breadcrumb open Simulate organization breadcrumb close
FOR 2886 PANDORA
  • FAUTo the central FAU website
  1. Friedrich-Alexander-Universität
  2. Interdisziplinäre Zentren
Suche öffnen
  • en
  • de
  • Campo
  • StudOn
  • FAUdir
  • Jobs
  • Map
  • Help
  1. Friedrich-Alexander-Universität
  2. Interdisziplinäre Zentren

FOR 2886 PANDORA

Navigation Navigation close
  • Team
    • Speaker
    • Coordination
    • Project A1
    • Project A2
    • Project A3
    • Project A4
    • Project B1
    • Project B2
    • (Project B3)
    • Project B4
    • Project B5
    • Project C1
    • Z-Project
    Portal Team
  • Projects
    • Project A1
    • Project A2
    • Project A3
    • Project A4
    • Project B1
    • Project B2
    • (Project B3)
    • Project B4
    • Project B5
    • Project C1
    • Z-Project
    Portal Projects
  • Publications
    • Project A1
    • Project A2
    • Project A3
    • Project A4
    • Project B1
    • Project B2
    • Project B3
    • Project B4
    • Project B5
    • Project C1
    • Z-Project
    Portal Publications
  1. Home
  2. Projects
  3. Project A4

Project A4

In page navigation: Projects
  • Project A1
  • Project A2
  • Project A3
  • Project A4
  • Project B1
  • Project B2
  • (Project B3)
  • Project B4
  • Project B5
  • Project C1
  • Z-Project

Project A4

Impact of IgA and IgG ACPA on the immune system and disease onset

In the first funding period, we discovered that IgA2 has a stronger pro-inflammatory capacity than IgA1 and that ACPA (anti citrullinated protein antibodies) display a higher IgA2 percentage compared to total serum IgA. The IgA2 percentage in ACPA correlated with disease severity of RA patients with established disease and with relapse severity after remission. Interestingly, serum ACPA levels of IgA and IgG isotype decline around onset of RA which may be a sign of increased transmigration of ACPA from the serum to affected tissue, such as the synovium. In a model of submaximal collagen-induced arthritis (CIA), co-immunization against citrullinated vimentin increased the incidence and disease severity, suggesting that ACPA directly contribute to the outbreak of arthritis. For the second funding period, we thus aim to further investigate the impact of IgA and IgG ACPA on the clinical onset of RA. We aim to investigate the effects of (auto)immunity against citrullinated proteins on the adaptive and innate immune system as well as synovitis employing the murine model of submaximal CIA. In addition, we will analyze spatial and temporal changes in the expression of ACPA antigens in the synovial tissue around the onset of arthritis. The results will be translated to patients with different stages of pre-RA and established RA.

2019-2022 (1st funding period): The role of IgA in the pathogenesis of RA

While the impact of IgG autoantibodies on the development of rheumatoid arthritis (RA) has been intensively studied, the role of IgA autoantibodies is still less well defined.

Bild Antikörper IgA1 und IgA2
human IgA system

In this project we aim to disentangle the role of IgA in RA focusing on differential actions of IgA subclasses A1 and A2.

Our preliminary data reveal an increased IgA2 to IgA1 ratio in autoantibodies in the sera of patients with RA that correlate with disease activity. IgA2 but not IgA1 from human serum exerts pro-inflammatory effects on macrophages and neutrophils. Taken together the data suggest that RA is characterized by a shift from immune-regulatory IgA1 to pro-inflammatory IgA2, with IgA2 being enriched in RA-specific autoantibodies. The aim of this project is to dissect the role of autoantibodies of the IgA subclasses in RA, with a special focus on the role of the IgA2 subclass in the transition from autoimmunity to inflammation.

Ulrike Steffen

Dr.rer.nat. Ulrike Steffen

Department of Medicine 3
Chair of Medicine III (Prof. Dr. Schett)

  • Phone number: +49 9131 85-39165
  • Email: ulrike.steffen@uk-erlangen.de

Rico Zapf

Rico Zapf

Department of Medicine 3
Chair of Medicine III (Prof. Dr. Schett)

  • Phone number: +49 9131 85-33795
  • Email: rico.zapf@uk-erlangen.de

Maria Sokolova

Maria Sokolova

Department of Medicine 3
Chair of Medicine III (Prof. Dr. Schett)

  • Phone number: +49 9131 85-33795
  • Email: maria.sokolova@uk-erlangen.de
Universitätsklinikum Erlangen
Medizinische Klinik 3

Universitätsstr. 25a
91054 Erlangen
  • Imprint
  • Privacy
  • Accessibility
  • Facebook
  • RSS Feed
  • RSS Feed
  • RSS Feed
  • Twitter
  • Twitter
  • Twitter
  • Xing
  • Xing
  • Xing
  • Facebook
  • Facebook
Up